Start-Up Previews (09/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target Cancer Metabolism," features profiles of Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals. Plus these Start-Ups Across Health Care: AlloCure, ArisGen, HistoSonics and NeuraviBiotechnology.
You may also be interested in...
Men who suffer from benign prostatic hyperplasia could soon have an alternative to surgery, if all goes well for HistoSonics Inc. The company is developing the Histotripsy system, an image-guided, robotic-manipulated procedure that uses ultrasound to excise and mechanically homogenize tissue without heat. HistoSonics believes its noninvasive office-based treatment option will be fast, effective, and cause fewer adverse effects than existing BPH treatments.
Neuravi Ltd.’s thrombus capture and removal device for acute stroke patients is designed to disengage offending clots from the wall of brain arteries, and then scaffold the clot inside a microfiber net during removal from the patient. The company thinks its technology represents a major advancement for the treatment of stroke because currently available products do not offer an effective clot disengagement system.
Cornerstone Pharmaceuticals Inc. is saying little about its lead drug candidate, CPI-613, which entered its first Phase I/II human clinical trial in late 2008, but the company and its backers believe they are developing a potentially game-changing class of new molecules and technology for delivering them. Its Altered Energy Metabolism Directed platform specifically utilizes the difference in cancer cells’ metabolic appetite to facilitate selective delivery of a novel small molecule (CPI-613 being the first example) into the cells’ mitochondria. Similarly the company’s Emulsiphan leverages those same metabolic differences to deliver drugs specifically to the cancer cell cytoplasm.